1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Hyperphosphatemia - Pipeline Review, H1 2015

Hyperphosphatemia - Pipeline Review, H1 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 80 pages

Hyperphosphatemia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Hyperphosphatemia - Pipeline Review, H1 2015’, provides an overview of the Hyperphosphatemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hyperphosphatemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hyperphosphatemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyperphosphatemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hyperphosphatemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Hyperphosphatemia - Pipeline Review, H1 2015
Table of Contents
Introduction 6
Global Markets Direct Report Coverage 6
Hyperphosphatemia Overview 7
Therapeutics Development 8
Pipeline Products for Hyperphosphatemia - Overview 8
Pipeline Products for Hyperphosphatemia - Comparative Analysis 9
Hyperphosphatemia - Therapeutics under Development by Companies 10
Hyperphosphatemia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Hyperphosphatemia - Products under Development by Companies 15
Hyperphosphatemia - Companies Involved in Therapeutics Development 16
Astellas Pharma Inc. 16
AstraZeneca PLC 17
Medice Arzneimittel Putter GmbH and Co. KG 18
Mitsubishi Tanabe Pharma Corporation 19
OPKO Health, Inc. 20
Panion and Bf Biotech Inc 21
Sanofi 22
Spectrum Pharmaceuticals, Inc. 23
Toray Industries, Inc. 24
Vifor Pharma AG 25
Hyperphosphatemia - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 32
Drug Profiles 34
ASP-3325 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
colestilan chloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Fe-SAMMS - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
fermagate - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
ferric citrate - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
JPH-101 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
niacinamide - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
PT-20 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
RDX-002 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
SPI-014 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
sucroferric oxyhydroxide - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
tenapanor hydrochloride - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
TRK-390 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
VS-501 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
VS-505 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Hyperphosphatemia - Recent Pipeline Updates 57
Hyperphosphatemia - Dormant Projects 68
Hyperphosphatemia - Discontinued Products 69
Hyperphosphatemia - Product Development Milestones 70
Featured News and Press Releases 70
Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis 70
Jan 27, 2015: Velphoro receives Swissmedic approval for the treatment of hyperphosphatemia in adult patients with chronic kidney disease on dialysis 70
Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch 71
Dec 04, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Auryxia (ferric citrate) Covering Orally Administrable Forms 72
Nov 19, 2014: New Drug Application Submitted For PA21 (development code) For Treatment Of Hyperphosphatemia 73
Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate 74
Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study 74
Oct 23, 2014: Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014 75
Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms 77
Sep 05, 2014: Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80

List of Tables
Number of Products under Development for Hyperphosphatemia, H1 2015 8
Number of Products under Development for Hyperphosphatemia - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Hyperphosphatemia - Pipeline by Astellas Pharma Inc., H1 2015 16
Hyperphosphatemia - Pipeline by AstraZeneca PLC, H1 2015 17
Hyperphosphatemia - Pipeline by Medice Arzneimittel Putter GmbH and Co. KG, H1 2015 18
Hyperphosphatemia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 19
Hyperphosphatemia - Pipeline by OPKO Health, Inc., H1 2015 20
Hyperphosphatemia - Pipeline by Panion and Bf Biotech Inc, H1 2015 21
Hyperphosphatemia - Pipeline by Sanofi, H1 2015 22
Hyperphosphatemia - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 23
Hyperphosphatemia - Pipeline by Toray Industries, Inc., H1 2015 24
Hyperphosphatemia - Pipeline by Vifor Pharma AG, H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Stage and Target, H1 2015 28
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 31
Number of Products by Stage and Molecule Type, H1 2015 33
Hyperphosphatemia Therapeutics - Recent Pipeline Updates, H1 2015 57
Hyperphosphatemia - Dormant Projects, H1 2015 68
Hyperphosphatemia - Discontinued Products, H1 2015 69

List of Figures
Number of Products under Development for Hyperphosphatemia, H1 2015 8
Number of Products under Development for Hyperphosphatemia - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Products, H1 2015 14
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Top 10 Targets, H1 2015 27
Number of Products by Stage and Top 10 Targets, H1 2015 27
Number of Products by Top 10 Mechanism of Actions, H1 2015 29
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31
Number of Products by Top 10 Molecule Types, H1 2015 32
Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.